A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever

References

• Buchmeier MJ, De La Torre JC, Peters CJ. Arenaviridae: The viruses and their replication. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin A, Roizman B, et al., editors. Fields virology.. New York: Lippincott, Williams & Wilkins; 2007:1792-827.
   Google Scholar
• Enria DA, Mills JN, Bausch DG, Shieh WJ, Peters CJ. Arenavirus infections. In: Guerrant RL, Walker DH, Weller PF, editors. Tropical infectious diseases: Principles, pathogens & practice.. New York: Elsevier; 2011. p. 1130.
   Google Scholar
• Bodewes R, Kik MJ, Raj VS, Schapendonk CM, Haagmans BL, Smits SL, Osterhaus AD. Detection of novel divergent arenaviruses in boid snakes with inclusion body disease in The Netherlands. J Gen Virol. 2013;94:1206-10. doi:10.1099/vir.0.051995-0. PMID:23468423
   PubMed Web of Science ®Google Scholar
• Hetzel U, Sironen T, Laurinmaki P, Liljeroos L, Patjas A, Henttonen H, Vaheri A, Artelt A, Kipar A, Butcher SJ, et al. Isolation, identification, and characterization of novel arenaviruses, the etiological agents of boid inclusion body disease. J Virol. 2013;87:10918-35. doi:10.1128/JVI.01123-13. PMID:23926354
   PubMed Web of Science ®Google Scholar
• Stenglein MD, Sanders C, Kistler AL, Ruby JG, Franco JY, Reavill DR, Dunker F, Derisi JL. Identification, characterization, and in vitro culture of highly divergent arenaviruses from boa constrictors and annulated tree boas: Candidate etiological agents for snake inclusion body disease. mBio. 2012;3:e00180-12. doi:10.1128/mBio.00180-12. PMID:22893382
   PubMed Web of Science ®Google Scholar
• Lenz O, ter Meulen J, Klenk HD, Seidah NG, Garten W. The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. Proc Natl Acad Sci U S A. 2001;98:12701-5. doi:10.1073/pnas.221447598. PMID:11606739
   PubMed Web of Science ®Google Scholar
• Bishop DHL. Viruses with ambisense RNA genomes. In: Notkins AL, Oldstone MBA, editors. Concepts in viral pathogenesis II.. New York (NY): Springer New York; 1986. p. 32-9.
   Google Scholar
• Bowen MD, Rollin PE, Ksiazek TG, Hustad HL, Bausch DG, Demby AH, Bajani MD, Peters CJ, Nichol ST. Genetic diversity among Lassa virus strains. J Virol. 2000;74:6992-7004. doi:10.1128/JVI.74.15.6992-7004.2000. PMID:10888638
   PubMed Web of Science ®Google Scholar
• Centers for Disease CaP. Lassa fever fact sheet. 2016. https://www.cdc.gov/vhf/lassa/pdf/factsheet.pdf
   Google Scholar
• Branco LM, Grove JN, Boisen ML, Shaffer JG, Goba A, Fullah M, Momoh M, Grant DS, Garry RF. Emerging trends in lassa fever: Redefining the role of immunoglobulin M and inflammation in diagnosing acute infection. Virol J. 2011;8:478. doi:10.1186/1743-422X-8-478. PMID:22023795
   PubMed Web of Science ®Google Scholar
• Cummins D. Rats, fever and sudden deafness in Sierra Leone. Trop Doct. 1992;22:83-4. PMID:1604723
   PubMed Web of Science ®Google Scholar
• Ibekwe TS, Okokhere PO, Asogun D, Blackie FF, Nwegbu MM, Wahab KW, Omilabu SA, Akpede GO. Early-onset sensorineural hearing loss in Lassa fever. Eur Arch Otorhinolaryngol. 2011;268:197-201. doi:10.1007/s00405-010-1370-4. PMID:20809263
   PubMed Web of Science ®Google Scholar
• Liao BS, Byl FM, Adour KK. Audiometric comparison of Lassa fever hearing loss and idiopathic sudden hearing loss: Evidence for viral cause. Otolaryngol Head Neck Surg. 1992;106:226-9. doi:10.1177/019459989210600303. PMID:1589210
   PubMed Web of Science ®Google Scholar
• Macher AM, Wolfe MS. Historical Lassa fever reports and 30-year clinical update. Emerg Infect Dis. 2006;12:835-7. doi:10.3201/eid1205.050052. PMID:16704848
   PubMed Web of Science ®Google Scholar
• Okokhere PO, Ibekwe TS, Akpede GO. Sensorineural hearing loss in Lassa fever: Two case reports. J Med Case Rep. 2009;3:36. doi:10.1186/1752-1947-3-36. PMID:19178735
   PubMedGoogle Scholar
• Ter Meulen J, Lukashevich I, Sidibe K, Inapogui A, Marx M, Dorlemann A, Yansane ML, Koulemou K, Chang-Claude J, Schmitz H. Hunting of peridomestic rodents and consumption of their meat as possible risk factors for rodent-to-human transmission of Lassa virus in the Republic of Guinea. Am J Trop Med Hyg. 1996;55:661-6. doi:10.4269/ajtmh.1996.55.661. PMID:9025695
   PubMed Web of Science ®Google Scholar
• Snell NJ. Ribavirin–current status of a broad spectrum antiviral agent. Expert Opin Pharmacother. 2001;2:1317-24. doi:10.1517/14656566.2.8.1317. PMID:11585000
   PubMedGoogle Scholar
• Fisher-Hoch SP, Gborie S, Parker L, Huggins J. Unexpected adverse reactions during a clinical trial in rural west Africa. Antiviral Res. 1992;19:139-47. doi:10.1016/0166-3542(92)90073-E. PMID:1444324
   PubMed Web of Science ®Google Scholar
• Cashman KA, Smith MA, Twenhafel NA, Larson RA, Jones KF, Allen RD 3rd, Dai D, Chinsangaram J, Bolken TC, Hruby DE, et al. Evaluation of Lassa antiviral compound ST-193 in a guinea pig model. Antiviral Res. 2011;90:70-9. doi:10.1016/j.antiviral.2011.02.012. PMID:21371508
   PubMed Web of Science ®Google Scholar
• Dai D, Burgeson JR, Gharaibeh DN, Moore AL, Larson RA, Cerruti NR, Amberg SM, Bolken TC, Hruby DE. Discovery and optimization of potent broad-spectrum arenavirus inhibitors derived from benzimidazole. Bioorg Med Chem Lett. 2013;23:744-9. doi:10.1016/j.bmcl.2012.11.095. PMID:23265895
   PubMed Web of Science ®Google Scholar
• Larson RA, Dai D, Hosack VT, Tan Y, Bolken TC, Hruby DE, Amberg SM. Identification of a broad-spectrum arenavirus entry inhibitor. J Virol. 2008;82:10768-75. doi:10.1128/JVI.00941-08. PMID:18715909
   PubMed Web of Science ®Google Scholar
• Gowen BB, Smee DF, Wong MH, Hall JO, Jung KH, Bailey KW, Stevens JR, Furuta Y, Morrey JD. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PloS One. 2008;3:e3725. doi:10.1371/journal.pone.0003725. PMID:19008960
   PubMed Web of Science ®Google Scholar
• Gowen BB, Wong MH, Jung KH, Sanders AB, Mendenhall M, Bailey KW, Furuta Y, Sidwell RW. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother. 2007;51:3168-76. doi:10.1128/AAC.00356-07. PMID:17606691
   PubMed Web of Science ®Google Scholar
• Mendenhall M, Russell A, Juelich T, Messina EL, Smee DF, Freiberg AN, Holbrook MR, Furuta Y, de la Torre JC, Nunberg JH, et al. T-705 (favipiravir) inhibition of arenavirus replication in cell culture. Antimicrob Agents Chemother. 2011;55:782-7. doi:10.1128/AAC.01219-10. PMID:21115797
   PubMed Web of Science ®Google Scholar
• Hensley LE, Smith MA, Geisbert JB, Fritz EA, Daddario-DiCaprio KM, Larsen T, Geisbert TW. Pathogenesis of Lassa fever in cynomolgus macaques. Virol J. 2011;8:205. doi:10.1186/1743-422X-8-205. PMID:21548931
   PubMed Web of Science ®Google Scholar
• Dupuy LC, Schmaljohn CS. DNA vaccines for biodefense. Expert Rev Vaccines. 2009;8:1739-54. doi:10.1586/erv.09.132. PMID:19943766
   PubMed Web of Science ®Google Scholar
• Saade F, Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines. 2012;11:189-209. doi:10.1586/erv.11.188. PMID:22309668
   PubMed Web of Science ®Google Scholar
• Pannetier D, Reynard S, Russier M, Journeaux A, Tordo N, Deubel V, Baize S. Human dendritic cells infected with the nonpathogenic mopeia virus induce stronger T-cell responses than those infected with Lassa virus. J Virol. 2011;85:8293-306. doi:10.1128/JVI.02120-10. PMID:21632749
   PubMed Web of Science ®Google Scholar
• Flatz L, Rieger T, Merkler D, Bergthaler A, Regen T, Schedensack M, Bestmann L, Verschoor A, Kreutzfeldt M, Brück W, et al. T cell-dependence of Lassa fever pathogenesis. PLoS Pathog. 2010;6:e1000836. doi:10.1371/journal.ppat.1000836. PMID:20360949
   PubMed Web of Science ®Google Scholar
• Russier M, Pannetier D, Baize S. Immune responses and Lassa virus infection. Viruses. 2012;4:2766-85. doi:10.3390/v4112766. PMID:23202504
   PubMed Web of Science ®Google Scholar
• Baize S, Marianneau P, Loth P, Reynard S, Journeaux A, Chevallier M, Tordo N, Deubel V, Contamin H. Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys. J Virol. 2009;83:5890-903. doi:10.1128/JVI.01948-08. PMID:19297492
   PubMed Web of Science ®Google Scholar
• ter Meulen J. Lassa fever: Implications of T-cell immunity for vaccine development. J Biotechnol. 1999;73:207-12. doi:10.1016/S0168-1656(99)00122-4. PMID:10486929
   PubMed Web of Science ®Google Scholar
• Cashman KA, Broderick KE, Wilkinson ER, Shaia CI, Bell TM, Shurtleff AC, Spik KW, Badger CV, Guttieri MC, Sardesai NY, et al. Enhanced efficacy of a codon-optimized DNA vaccine encoding the glycoprotein precursor gene of lassa virus in a guinea pig disease model when delivered by dermal electroporation. Vaccines. 2013;1:262-77. doi:10.3390/vaccines1030262. PMID:26344112
   PubMedGoogle Scholar
• Amante DH, Smith TR, Mendoza JM, Schultheis K, McCoy JR, Khan AS, Sardesai NY, Broderick KE. Skin transfection patterns and expression kinetics of electroporation-enhanced plasmid delivery using the CELLECTRA-3P, a portable next-generation dermal electroporation device. Hum Gene Ther Methods. 2015;26:134-46. doi:10.1089/hgtb.2015.020. PMID:26222896
   PubMed Web of Science ®Google Scholar
• Diehl MC, Lee JC, Daniels SE, Tebas P, Khan AS, Giffear M, Sardesai NY, Bagarazzi ML. Tolerability of intramuscular and intradermal delivery by CELLECTRA((R)) adaptive constant current electroporation device in healthy volunteers. Hum Vaccin Immunother. 2013;9:2246-52. doi:10.4161/hv.24702. PMID:24051434
   PubMed Web of Science ®Google Scholar
• Bausch DG, Hadi CM, Khan SH, Lertora JJ. Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. Clin Infect Dis. 2010;51:1435-41. doi:10.1086/657315. PMID:21058912
   PubMed Web of Science ®Google Scholar
• Hadi CM, Goba A, Khan SH, Bangura J, Sankoh M, Koroma S, Juana B, Bah A, Coulibaly M, Bausch DG. Ribavirin for Lassa fever postexposure prophylaxis. Emerg Infect Dis. 2010;16:2009-11. doi:10.3201/eid1612.100994. PMID:21122249
   PubMed Web of Science ®Google Scholar
• McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM, Elliott LH, Belmont-Williams R. Lassa fever. Effective therapy with ribavirin. N Engl J Med. 1986;314:20-6. doi:10.1056/NEJM198601023140104. PMID:3940312
   PubMed Web of Science ®Google Scholar
• Bredenbeek PJ, Molenkamp R, Spaan WJ, Deubel V, Marianneau P, Salvato MS, Moshkoff D, Zapata J, Tikhonov I, Patterson J, et al. A recombinant yellow fever 17D vaccine expressing lassa virus glycoproteins. Virology. 2006;345:299-304. doi:10.1016/j.virol.2005.12.001. PMID:16412488
   PubMed Web of Science ®Google Scholar
• Carrion R Jr, Bredenbeek P, Jiang X, Tretyakova I, Pushko P, Lukashevich IS. Vaccine platforms to control arenaviral hemorrhagic fevers. J Vaccines Vaccin. 2012;3:1000160. doi:10.4172/2157-7560.1000160. PMID:23420494
   PubMedGoogle Scholar
• Carrion R Jr, Patterson JL, Johnson C, Gonzales M, Moreira CR, Ticer A, Brasky K, Hubbard GB, Moshkoff D, Zapata J, et al. A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine. 2007;25:4093-102. doi:10.1016/j.vaccine.2007.02.038. PMID:17360080
   PubMed Web of Science ®Google Scholar
• Fisher-Hoch SP, Hutwagner L, Brown B, McCormick JB. Effective vaccine for lassa fever. J Virol. 2000;74:6777-83. doi:10.1128/JVI.74.15.6777-6783.2000. PMID:10888616
   PubMed Web of Science ®Google Scholar
• Fisher-Hoch SP, McCormick JB. Towards a human Lassa fever vaccine. Rev Med Virol. 2001;11:331-41. doi:10.1002/rmv.329. PMID:11590670
   PubMed Web of Science ®Google Scholar
• Fisher-Hoch SP, McCormick JB. Lassa fever vaccine. Expert Rev Vaccines. 2004;3:189-97. doi:10.1586/14760584.3.2.189. PMID:15056044
   PubMedGoogle Scholar
• Geisbert TW, Jones S, Fritz EA, Shurtleff AC, Geisbert JB, Liebscher R, Grolla A, Ströher U, Fernando L, Daddario KM, et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2005;2:e183. doi:10.1371/journal.pmed.0020183. PMID:15971954
   PubMed Web of Science ®Google Scholar
• Jiang X, Dalebout TJ, Bredenbeek PJ, Carrion R Jr, Brasky K, Patterson J, Goicochea M, Bryant J, Salvato MS, Lukashevich IS. Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine. 2011;29:1248-57. doi:10.1016/j.vaccine.2010.11.079. PMID:21145373
   PubMed Web of Science ®Google Scholar
• Lukashevich IS. Advanced vaccine candidates for Lassa fever. Viruses. 2012;4:2514-57. doi:10.3390/v4112514. PMID:23202493
   PubMed Web of Science ®Google Scholar
• Lukashevich IS, Carrion R Jr, Salvato MS, Mansfield K, Brasky K, Zapata J, Cairo C, Goicochea M, Hoosien GE, Ticer A, et al. Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine. 2008;26:5246-54. doi:10.1016/j.vaccine.2008.07.057. PMID:18692539
   PubMed Web of Science ®Google Scholar
• Lukashevich IS, Patterson J, Carrion R, Moshkoff D, Ticer A, Zapata J, Brasky K, Geiger R, Hubbard GB, Bryant J, et al. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J Virol. 2005;79:13934-42. doi:10.1128/JVI.79.22.13934-13942.2005. PMID:16254329
   PubMed Web of Science ®Google Scholar
• Marzi A, Feldmann F, Geisbert TW, Feldmann H, Safronetz D. Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses. Emerg Infect Dis. 2015;21:305-7. doi:10.3201/eid2102.141649. PMID:25625358
   PubMed Web of Science ®Google Scholar
• McCormick JB, Mitchell SW, Kiley MP, Ruo S, Fisher-Hoch SP. Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys. J Med Virol. 1992;37:1-7. doi:10.1002/jmv.1890370102. PMID:1619397
   PubMed Web of Science ®Google Scholar
• Olschlager S, Flatz L. Vaccination Strategies against highly pathogenic arenaviruses: The next steps toward clinical trials. PLoS pathogens. 2013;9:e1003212. doi:10.1371/journal.ppat.1003212. PMID:23592977
   PubMed Web of Science ®Google Scholar
• Mendoza JM, Amante DH, Kichaev G, Knott CL, Kiosses WB, Smith TR, Sardesai NY, Broderick KE. Elucidating the kinetics of expression and immune cell infiltration resulting from plasmid gene delivery enhanced by surface dermal electroporation. Vaccine. 2013;1:384-97. doi:10.3390/vaccines1030384. PMID:26344120
   PubMedGoogle Scholar
• Amante DH, Smith TR, Kiosses BB, Sardesai NY, Humeau LM, Broderick KE. Direct transfection of dendritic cells in the epidermis after plasmid delivery enhanced by surface electroporation. Hum Gene Ther Methods. 2014;25:315-6. doi:10.1089/hgtb.2014.061. PMID:25470335
   PubMed Web of Science ®Google Scholar
• Broderick KE, Khan AS, Sardesai NY. DNA vaccination in skin enhanced by electroporation. Methods Mol Biol. 2014;1143:123-30. doi: 10.1007/978-1-4939-0410-5_8. PMID:24715285
   PubMedGoogle Scholar
• Kulkarni V, Rosati M, Jalah R, Ganneru B, Alicea C, Yu L, Guan Y, LaBranche C, Montefiori DC, King AD, et al. DNA vaccination by intradermal electroporation induces long-lasting immune responses in rhesus macaques. J Med Primatol. 2014;43:329-40. doi:10.1111/jmp.12123. PMID:24810337
   PubMed Web of Science ®Google Scholar
• McCoy JB, Mendoza JM, Spik KW, Badger C, Gomez A, Schmaljohn CS, Sardesai NY, Broderick KE. A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skin. Hum Vaccin Immunother. 2014;10:3039-47. doi:10.4161/hv.29671. PMID:25483486
   PubMed Web of Science ®Google Scholar
• Roos AK, Moreno S, Leder C, Pavlenko M, King A, Pisa P. Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. Mol Ther. 2006;13:320-7. doi:10.1016/j.ymthe.2005.08.005. PMID:16185933
   PubMed Web of Science ®Google Scholar
• Tollefsen S, Tjelle T, Schneider J, Harboe M, Wiker H, Hewinson G, Huygen K, Mathiesen I. Improved cellular and humoral immune responses against Mycobacterium tuberculosis antigens after intramuscular DNA immunisation combined with muscle electroporation. Vaccine. 2002;20:3370-8. doi:10.1016/S0264-410X(02)00289-X. PMID:12213407
   PubMed Web of Science ®Google Scholar
• Lin F, Shen X, McCoy JR, Mendoza JM, Yan J, Kemmerrer SV, Khan AS, Weiner DB, Broderick KE, Sardesai NY. A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle. Vaccine. 2011;29:6771-80. doi:10.1016/j.vaccine.2010.12.057. PMID:21199706
   PubMed Web of Science ®Google Scholar
• Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, Edwards L, Parker RL, Denny L, Giffear M, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: A randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015;386:2078-88. doi:10.1016/S0140-6736(15)00239-1. PMID:26386540
   PubMed Web of Science ®Google Scholar
• Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC, Giffear M, Pankhong P, Khan AS, Broderick KE, et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med. 2012;4:155ra38. doi:10.1126/scitranslmed.3004414. PMID:23052295
   PubMed Web of Science ®Google Scholar
• Di Meglio P, Perera GK, Nestle FO. The multitasking organ: Recent insights into skin immune function. Immunity. 2011;35:857-69. doi:10.1016/j.immuni.2011.12.003. PMID:22195743
   PubMed Web of Science ®Google Scholar
• Lukashevich IS. The search for animal models for Lassa fever vaccine development. Expert Rev Vaccines. 2013;12:71-86. doi:10.1586/erv.12.139. PMID:23256740
   PubMed Web of Science ®Google Scholar
• Schmaljohn C, Vanderzanden L, Bray M, Custer D, Meyer B, Li D, Rossi C, Fuller D, Fuller J, Haynes J, et al. Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge. J Virol. 1997;71:9563-9. PMID:9371620
   PubMed Web of Science ®Google Scholar
• Hirao LA, Wu L, Khan AS, Satishchandran A, Draghia-Akli R, Weiner DB. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine. 2008;26:440-8. doi:10.1016/j.vaccine.2007.10.041. PMID:18082294
   PubMed Web of Science ®Google Scholar
• Academies NRCotN. Guide for the care and use of laboratory animals.. Washington (DC): The National Academies Press; 2011.
   Google Scholar
• Tomori O, Johnson KM, Kiley MP, Elliott LH. Standardization of a plaque assay for Lassa virus. J Med Virol. 1987;22:77-89. doi:10.1002/jmv.1890220110. PMID:3585290
   PubMed Web of Science ®Google Scholar
• Hooper JW, Kamrud KI, Elgh F, Custer D, Schmaljohn CS. DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects against seoul virus infection. Virology. 1999;255:269-78. doi:10.1006/viro.1998.9586. PMID:10069952
   PubMed Web of Science ®Google Scholar